DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria Universidad Francisco de Vitoria The Lancet The Lancet, Elsevier, 2020, 396 (10253), pp.759-769. ⟨10.1016/S0140-6736(20)31792-X⟩ Lancet, 396(10253), 759-769. Elsevier Science DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria instname Olivotto, I, Oreziak, A, Barriales-Villa, R, Abraham, T P, Masri, A, García Pavia, P, Saberi, S, Lakdawala, N K, Wheeler, M T, Owens, A, Kubanek, M, Wojakowski, W, Jensen, M K, Gimeno-Blanes, J, Afshar, K, Myers, J, Hegde, S M, Solomon, S D, Sehnert, A J, Zhang, D, Li, W, Bhattacharya, M, Edelberg, J M, Waldman, C B, Lester, S J, Wang, A, Ho, C Y, Jacoby, D & EXPLORER-HCM 2020, ' Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 396, no. 10253, pp. 759-769 . https://doi.org/10.1016/S0140-6736(20)31792-X